Title |
Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
|
---|---|
Published in |
Respiratory Research, October 2009
|
DOI | 10.1186/1465-9921-10-101 |
Pubmed ID | |
Authors |
Jürgen Behr, Maurits Demedts, Roland Buhl, Ulrich Costabel, Richard PN Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, Francois Laurent, Andrew G Nicholson, Eric K Verbeken, Johny Verschakelen, CDR Flower, Stefano Petruzzelli, Paul De Vuyst, van den JMM Bosch, Eulogio Rodriguez-Becerra, Ida Lankhorst, Marco Sardina, Gabrielle Boissard |
Abstract |
The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 2% |
India | 1 | 2% |
Peru | 1 | 2% |
Belgium | 1 | 2% |
Spain | 1 | 2% |
United States | 1 | 2% |
Unknown | 56 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 11 | 18% |
Student > Master | 9 | 15% |
Other | 8 | 13% |
Student > Ph. D. Student | 7 | 11% |
Student > Doctoral Student | 4 | 6% |
Other | 15 | 24% |
Unknown | 8 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 52% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Business, Management and Accounting | 3 | 5% |
Nursing and Health Professions | 3 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Other | 6 | 10% |
Unknown | 12 | 19% |